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IllustratIve case 
A	75-year-old	woman	comes	to	see	you	
1	month	after	she	had	surgery	to	repair	
a	hip	fracture.	She	was	diagnosed	with	
osteoporosis	3	years	prior	to	the	hip	
fracture	and	is	currently	taking	calcium	
and	vitamin	D.	She	tried	taking	an	oral	
bisphosphonate	but	couldn’t	tolerate		
the	gastrointestinal	side	effects.	What	
treatment	can	you	recommend	to	reduce	
her	risk	of	sustaining	another	fracture?
background 
z  First fracture  
heightens risk
Patients with a prior hip fracture have 
2.5 times the risk of a new fracture com-
pared to age-matched persons without a 
previous hip fracture.2 Women who have 
hip fractures are 3 times more likely to die 
in the first 6 months after the fracture than 
women of the same age and health status 
without fractures.3 Ten million people in 
the US have osteoporosis and 300,000 per 
year suffer hip fracture.4
Guidelines from the National Osteo-
porosis Foundation (NOF) and the In-
stitute for Clinical Systems Improvement 
(ICSI) include these recommendations for 
hip fracture patients: discuss adequacy of 
total calcium and vitamin D intake; ad-
dress home safety and falls prevention; 
and encourage specific exercises for muscle 
strength. They also recommend treating all 
patients with a prior hip or vertebral frac-
ture with an antiresorptive agent. Options 
include oral bisphosphonates (alendro-
nate, ibandronate, or risedronate), calci-
tonin intranasal spray or subcutaneous 
calcitonin, hormone therapy, parathyroid 
hormone, and raloxifene.5,6
clInIcal context 
z  Are we doing our best?
Most patients with hip fracture are not 
properly evaluated or treated for osteo-
porosis. A 2002 study of 500 hip frac-
ture patients treated at 4 Midwestern 
health systems found that only 12% to 
24% of patients had a DXA (dual-en-
ergy x-ray absorptiometry) scan either 
before or after hip fracture, 5% to 27% 
of the patients received documented 
advice to take adequate calcium and 
vitamin D, and 5% to 37% received a 
Annual zoledronic acid infusion 
lowers risk of fracture, death
Sarah-Anne Schumann, MD 
and John Hickner, MD, MSc
Department of Family Medicine, 
The University of Chicago
The number  
needed to treat 
strikes us  
as a good bargain
For	patients	with	a	recent	
hip	fracture,	intravenous	
zoledronic	acid	annually	is	an	
option	for	reducing	the	risk	
of	new	fractures	and	death.1
Strength	of	recommendation	(Sor)	
b: based	on	one	well-designed	randomized	controlled	trial
lyles	KW,	colon-emeric	cS,	magaziner	JF,	et	
al.	Zoledronic	acid	and	clinical	fractures	and	
mortality	after	hip	fracture.	N Engl J Med	2007;	
357:1799–1809.	epub	Sep	17.
Practice changer 
PURLS methodology
The criteria and findings  
leading to the selection of this 
study as a Priority Update  
from the Research Literature 
can be accessed at  
www.jfponline.com/purls.
New feature
Editorial PURLs: translating research into reality Page 981
fast track
1014 vol	56,	No	12	/	December	2007		the Journal of famIly PractIce
P
U
R
Ls
®
prescription for any antiresorptive med-
ication (bisphosphonate [2% to 10%], 
estrogen, calcitonin, or raloxifene).7  
Bisphosphonates are effective 
but compliance is poor
Bisphosphonates are effective in pre-
venting recurrence of hip fracture. One 
cohort study that included over 35,000 
women over age 45 who had received 
a bisphosphonate prescription showed 
that patients who are adherent to treat-
ment have a 44.5% relative risk reduc-
tion over 2 years and an absolute risk 
reduction of 0.8%, for an NNT of 125. 
However, compliance with oral 
bisphosphonate therapy is poor; only 
20% of the women in this study per-
sisted with the therapy for 24 months.8 
Patients must take these medications first 
thing in the morning with 8 ounces of 
water and then remain upright for 30 
to 60 minutes before eating or drinking. 
Gastrointestinal side effects, including 
dyspepsia, nausea, and reflux disease, oc-
cur in about 25% of patients, and there 
is a small risk of developing gastric or 
duodenal ulcers. 
Risk of fracture 
was reduced by 
35% and risk of 
death by 28%  
First fracture  
foretells another
This	mature	hip	is	still	strong,	
but	losing	trabecular	support	as	
osteoclasts	destroy	more	bone	
than	osteoblasts	can	rebuild.		
A	first	fracture	is	a	sign	of	
continuing	bone	loss	and	a	
heightened	likelihood	of		
additional	fractures
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study summary
The HORIZON Recurrent Fracture Trial 
was an international, randomized, double 
blind, placebo-controlled trial of 2127 
patients with a recent hip fracture.  
• The primary endpoint was a new 
clinical fracture.  
• Secondary endpoints included the 
change in bone mineral density in the 
non-fractured hip, new vertebral and hip 
fractures, and pre-specified safety end-
points, including death.  
Patients. Women and men age 50 or 
older who had undergone a surgical re-
pair of a minimal trauma hip fracture in 
the previous 90 days were eligible for the 
study. Ninety-one percent of the patients 
were white, 76% were female, and the 
mean age was 74.5 years. Forty-one per-
cent of patients had a T score at the femo-
ral neck of –2.5 or less at baseline (meeting 
diagnostic criteria for osteoporosis).  
method. Patients were randomized to 
receive either intravenous zoledronic acid 
5 mg or placebo within 90 days of sur-
gical repair of a hip fracture and yearly 
thereafter for the duration of the study. 
Patients with serum 25-hydroxyvitamin 
D levels <15 ng/mL received a load-
ing dose of vitamin D (50,000–125,000 
IU) 14 days before the first dose of the 
study drug. All patients were given daily 
calcium (1000–1500 mg) and vitamin 
D (800–1200 IU) supplements. Simul-
taneous treatment with nasal calcitonin, 
selective estrogen-receptor modulators, 
hormone replacement, tobolone, and ex-
ternal hip protectors was permitted “at 
the discretion of the investigators,” and 
10.5% of the study patients did receive 
one of these other osteoporosis therapies. 
Patients were followed for up to 5 
years. Bone mineral density was tested 
by DXA at the hip and femoral neck at 
baseline and then annually. The median 
follow-up time was 1.9 years; 71.3% of 
patients completing the trial, and 3% of 
patients were lost to follow-up.
results. The patients assigned to 
zoledronic acid had a 5.3% absolute 
risk reduction for new clinical fractures, 
osteoblasts
build bone
osteoclasts 
destroy 
bone
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Annual zoledronic acid 
yielding an NNT of 19 over 2 years to 
prevent one new clinical fracture (TABLE 
1). Bone mineral density of the contra-
lateral hip increased in the zoledronic 
acid group by 2.6% after 1 year, 4.7% 
after 2 years, and 5.5% after 3 years 
and declined in the placebo group by 
1.0%, 0.7%, and 0.9% respectively.
There was a 3.7% absolute risk re-
duction of death, with an NNT of 27 for 
2 years to prevent one death.  
Adverse events that were more com-
mon in the zoledronic acid group included 
fever (8.7% vs 3.1%) and musculoskel-
etal pain (3.1% vs. 1.2%). There were 
no reported cases of jaw osteonecrosis in 
either group and no statistically signifi-
cant delay in the healing of fractures with 
zoledronic acid. Both groups had similar 
rates of renal and cardiovascular events, 
including atrial fibrillation and stroke.
Novartis provided funding for the 
study. An independent data and safety 
monitoring board oversaw the conduct 
and safety of the study and recommend-
ed that it be stopped early after hav-
ing surpassed the pre-specified efficacy 
boundaries. Independent statisticians 
confirmed the data analysis that was per-
formed by the sponsor.1
what’s new 
z  The adherence advantage
The obvious advantage of zoledronic acid 
over other bisphosphonates is the high 
level of adherence that is possible under 
the controlled environment of a once 
yearly infusion administered under medi-
cal supervision. Considering the low rates 
of adherence to oral bisphosphonates, this 
is a significant medical advance. 
This study shows that a yearly infu-
sion of zoledronic acid is highly effective 
in preventing subsequent clinical fractures 
in patients who have recently suffered a 
hip fracture. It is the first randomized-
controlled trial of a bisphosphonate for 
No jaw  
osteonecrosis  
was reported  
in either group
Bisphosphonates for osteoporosis: Routes, dosage, and cost 
generIc  brand  route of  dose and aPProxImate 
name name admInIstratIon frequency annual cost
alendronate	 Fosamax	 oral	 10	mg/d	or	70	mg/week	 $960–$1120
Ibandronate	 boniva	 oral	or	Iv	 2.5	mg/d,	150	mg	monthly		 $1140–$1200	Po,	
	 	 	 (Po)	or	3	mg	Iv	every	3	months	 $1980	Iv
risedronate	 Actonel	 oral	 5	mg/d	or	35	mg/week	 $1000–$1100
Zoledronic acid	 reclast	 Iv	 5	mg	once	a	year	 $1200
tAbLe 2
The HORIZON study: Rates of fracture and death were  
lower in the zoledronic group compared to placebo1
outcome Placebo ZoledronIc haZard 
 (n=1062) acId (n=1065) ratIo (95% cI) P value
any fracture	 139	(13.9%)	 92	(8.6%)	 0.65	(0.50-0.84)	 .001
hip fracture	 33	(3.5%)	 23	(2.0%)	 0.70	(0.41-1.19)	 .18
vertebral  39	(3.8%)	 21	(1.7%)	 0.54	(0.32–0.92)	 .02 
fracture
death	 141	(13.3%)	 101	(9.6%)	 0.72	(0.56-0.93)	 .01
rates	of	fracture	were	calculated	by	Kaplan-meier	methods	at	24	months	and	are	not	simple	percentages
tAbLe 1
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secondary prevention in patients with re-
cent hip fracture, regardless of their bone 
mineral density status.
In a previous 3-year randomized con-
trolled trial of 5mg zoledronic acid once 
yearly vs placebo for postmenopausal 
women with osteoporosis, the risk of 
vertebral fractures was reduced by 70% 
(3.3% vs 10.9% placebo) and the risk of 
hip fracture was reduced by 41% (1.4% 
vs 2.5% placebo).9 
The NNT of 19 for 2 years to prevent 
one clinical fracture and NNT of 27 for 2 
years to prevent one death strikes us as a 
good bargain compared to many modern 
medical interventions. Are these results 
too good to be true? We don’t think so. 
No serious design flaws
This was a well done trial with no serious 
flaws in design. The number of deaths, 
however, was relatively small, so the NNT 
may be as high as 50 by our rough calcu-
lations. As a “worst case” for the benefit, 
however, this still seems worthwhile. 
caveats
Patients with uncorrected hypocalce-
mia or creatinine clearance <35 mL/min 
should not take bisphosphonates, in-
cluding zoledronic acid. Although this 
study did not show any evidence of an 
increased risk of atrial fibrillation or re-
port any cases of osteonecrosis of the 
jaw, providers should monitor patients 
for these potential adverse events.  
challenges to ImPlementatIon 
z  $1200 per dose
The FDA approved Reclast (zoledronic 
acid 5 mg) as a once-yearly treatment for 
postmenopausal osteoporosis and Paget’s 
disease in August 2007. (Zometa is the 
brand name for zoledronic acid 4 mg that 
is indicated for multiple myeloma, bone 
metastasis, and hypercalcemia of malig-
nancy.) Medicare and most insurance 
plans will reimburse Reclast infusion for 
these FDA-approved indications when 
billed by a provider using a CPT code. 
It is administered intravenously over 15-
minutes and there are no risks beyond 
those associated with local infiltration. 
The greatest barrier to implement-
ing this practice for solo physicians or 
small group practices will likely be the 
up front expense of buying the drug; 
one dose is approximately $1200. Pa-
tients can be referred to larger practices 
or hospitals with the capital to have 
zoledronic acid on hand and the capa-
bility of providing the infusion.
The cost is comparable to the annu-
al cost of oral bisphosphonates and less 
than the cost of the other IV bisphos-
phonate (ibandronate), which is admin-
istered every 3 months (TABLE 2). n
Purls methodology
This	 study	 was	 selected	 and	 evaluated	 using	 FPIN’s	
Priority	Updates	 from	 the	research	literature	Surveil-
lance	 System	 methodology.	 The	 criteria	 and	 findings	
leading	to	the	selection	of	this	study	as	a	PUrl	can	be	
accessed	at	www.jfponline.com/purls.
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